Tender Overview
Organization: Indian Army (Department Of Military Affairs) seeks supply of a broad range of pharmaceutical, ophthalmic, and dermal products, including creams, lotions, eye drops, gels, nail lacquers, and oral rehydration solutions. Estimated value: ₹65,62,139 with an EMD of ₹60,924. Location: India. Quantity flexibility: up to 25% order quantity at contracted rates; delivery extensions up to original delivery period. This procurement encompasses 29 items across multiple therapeutic categories, with emphasis on ophthalmic emulsions, retinoids, antifungals, steroids, and cream formulations. The scope includes both consumer-packaged and sterile ophthalmic products, with emphasis on product safety and regulatory compliance.
Technical Specifications & Requirements
- Product categories include: ophthalmic solutions and suspensions (e.g., latanoprost, nepafenac, olopatadine with ketorolac, moxifloxacin combos), topical creams/lotions (retinol/retinoids, acne therapies, kojic acid, pimecrolimus, benzoyl peroxide blends), gels, shampoos, and oral formulations (divalproex sodium tablets).
- No explicit technical specifications listed in the tender summary; emphasis on regulatory compliance (valid drug licenses) and packaging standards (LDPE/FFS, 5 ml–10 ml ophthalmic bottle sizes mentioned).
- BOQ lists 29 items; no numeric quantities provided per item in the data. Estimated value signals aggregate market scope; EMD indicates bidder financial commitment. Delivery and option timing governed by buyer’s quantity variation clause.
- Key compliance cues include manufacturer licensure, drug regulatory approvals, and supply capability for diverse pharmaceutical dosage forms.
Terms, Conditions & Eligibility
- EMD: ₹60,924 (as per tender data).
- Option clause: Purchaser may increase/decrease quantity by up to 25%, during contract, at contracted rates; delivery period adjustments follow a formula, minimum 30 days.
- Delivery timelines link to last delivery order date; extended time depends on option exercise.
- Buyer requires valid drug license and compliance with regulatory standards; exact standards not specified in the data.
- Submission requires typical pharma bid documents (GST, PAN, experience, financials) per T&C, plus OEM authorizations if applicable.
- No explicit warranty or penalty schedule provided beyond the option clause; bidders should infer standard contract terms and ensure regulatory compliance.